(Q35903984)

11 August 2017

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia (English)

1 reference

11 August 2017

0 references

1 reference

1 reference

20

John C Byrd

1 reference

11 August 2017

4

Nyla A Heerema

1 reference

11 August 2017

17

Kristie A Blum

1 reference

11 August 2017

12

Jeffrey A Jones

1 reference

11 August 2017

18

Michael R Grever

1 reference

11 August 2017

14

Samantha M Jaglowski

1 reference

11 August 2017

21

Jennifer A Woyach

1 reference

11 August 2017

15

Leslie A Andritsos

1 reference

11 August 2017

6

Lynne Abruzzo

1 reference

11 August 2017

16

Farrukh Awan

1 reference

11 August 2017

3

Gerard Lozanski

1 reference

11 August 2017

7

Arletta Lozanski

1 reference

11 August 2017

5

Weiqiang Zhao

1 reference

11 August 2017

1

Kami J Maddocks

1 reference

11 August 2017

2

Amy S Ruppert

1 reference

11 August 2017

8

Melanie Davis

1 reference

11 August 2017

11

Rose Mantel

1 reference

11 August 2017

Amber Gordon

9

1 reference

11 August 2017

Lisa L Smith

series ordinal

10

1 reference

11 August 2017

Joseph M Flynn

series ordinal

13

1 reference

11 August 2017

Amy J Johnson

series ordinal

19

1 reference

11 August 2017

1 April 2015

1 reference

11 August 2017

1 reference

11 August 2017

1

1 reference

11 August 2017

1

1 reference

11 August 2017

80-87

1 reference

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4520535

Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26182309

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1001/JAMAONCOL.2014.218

1 reference

11 August 2017

1 reference

11 August 2017

1 reference